

# Working memory in children with attention-deficit/hyperactivity disorder (ADHD): the impact of methylphenidate (MPH)

<b>Submission date</b> 23/01/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 23/01/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 12/12/2019	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Kim Cornish

### Contact details

Developmental Psychiatry  
Division of Psychiatry  
E Floor, South Block  
South Block  
Queens Medical Centre  
Nottingham  
United Kingdom  
NG7 2UH  
+44 (0)115 924 9924  
kim.cornish@mcgill.ca

## Additional identifiers

### Protocol serial number

RBP 98X24

## Study information

**Scientific Title**

Working memory in children with attention-deficit/hyperactivity disorder (ADHD): the impact of methylphenidate (MPH)

**Study objectives**

To address the following questions: What are the effects of methylphenidate on working memory in children with ADHD? Is there evidence for differential effects of MPH on working memory function? What is the relationship between the effects of MPH on working memory, behavioural inhibition, non-executive memory performance and hyperactive/impulsive behaviour?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Behavioural disorders

**Interventions**

1. Methylphenidate (MPH) treatment
2. No methylphenidate treatment

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

1. Information about effects of MPH on cognitive function (including the possibility of cognitive toxicity) in children with ADHD
2. Greater understanding of the underlying cognitive processes in ADHD  
This knowledge of underlying mechanisms will lead to improved specificity of early detection, diagnosis and treatment of ADHD
3. Identification of potential cognitive deficits in ADHD. If persisting cognitive deficits are identified. These will be rational targets for supplementary treatment interventions
4. Suggestion of tests to monitor the effects of MPH on cognitive function which could be developed for use in everyday clinical practice.

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

29/02/2000

## Eligibility

**Key inclusion criteria**

60 boys aged between 7-12 years, receiving MPH, with a diagnosis of Hyperkinetic disorder or the equivalent ADHD combined sub-type, will be recruited from out-patient psychiatric clinics in the Trent region.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

7 years

**Upper age limit**

12 years

**Sex**

Male

**Key exclusion criteria**

Does not match inclusion criteria

**Date of first enrolment**

01/09/1998

**Date of final enrolment**

29/02/2000

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Queens Medical Centre**  
Nottingham  
United Kingdom  
NG7 2UH

## **Sponsor information**

### **Organisation**

NHS R&D Regional Programme Register - Department of Health (UK)

## **Funder(s)**

### **Funder type**

Hospital/treatment centre

### **Funder Name**

NHS Executive Trent (UK)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration